Gotowa bibliografia na temat „Pro-hemostatic agents”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Pro-hemostatic agents”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Pro-hemostatic agents"
Laurenti, Juliana Bergamasco, Gabriel Zazeri, Ana Paula Ribeiro Povinelli, Moacir Fernandes de Godoy, Domingo Marcolino Braile, Tânia R. Flores da Rocha, Élbio Antônio D' Amico i José Geraldo Nery. "Enhanced pro-coagulant hemostatic agents based on nanometric zeolites". Microporous and Mesoporous Materials 239 (luty 2017): 263–71. http://dx.doi.org/10.1016/j.micromeso.2016.10.020.
Pełny tekst źródłaBudko, Elena V., Daria A. Chernikova, Leonid M. Yampolsky i Valentina Y. Yatsyuk. "Local hemostatic agents and ways of their improvement". I.P. Pavlov Russian Medical Biological Herald 27, nr 2 (2.07.2019): 274–85. http://dx.doi.org/10.23888/pavlovj2019272274-285.
Pełny tekst źródłaOtrocka-Domagała, I., P. Jastrzębski, Z. Adamiak, K. Paździor-Czapula, M. Gesek, M. Mikiewicz i T. Rotkiewicz. "Safety of the long-term application of QuikClot Combat Gauze, ChitoGauze PRO and Celox Gauze in a femoral artery injury model in swine – a preliminary study". Polish Journal of Veterinary Sciences 19, nr 2 (1.06.2016): 337–43. http://dx.doi.org/10.1515/pjvs-2016-0041.
Pełny tekst źródłaSchoenwaelder, Simone M., Kate E. Jarman, Elizabeth E. Gardiner, My Hua, Jianlin Qiao, Michael J. White, Emma C. Josefsson i in. "Bcl-xL–inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets". Blood 118, nr 6 (11.08.2011): 1663–74. http://dx.doi.org/10.1182/blood-2011-04-347849.
Pełny tekst źródłaAgraharkar, M., i M. A. Martinez. "Spontaneous Re-Canalization of Thrombosed Polytetrafluoroethylene (PTFE) Grafts". Journal of Vascular Access 2, nr 3 (lipiec 2001): 114–18. http://dx.doi.org/10.1177/112972980100200306.
Pełny tekst źródłaSivakumar, Walavan, Jian Guan, Jean-Philippe Langevin, Neil A. Martin, Garni Barkhoudarian, Daniel F. Kelly, John Franklin Berry i Aditya K. Iyer. "873 Code Brain Ultra-Early Clinical Pathway for Patient Identification and Management in Spontaneous Non-traumatic Intracranial Hemorrhage Single-Institution Study". Neurosurgery 70, Supplement_1 (kwiecień 2024): 173. http://dx.doi.org/10.1227/neu.0000000000002809_873.
Pełny tekst źródłaThalji, Nabil K., Lacramioara Ivanciu, Reema Jasuja, Sunita Patel-Hett, Joachim Fruebis, Debra Pittman i Rodney M. Camire. "Zymogen-like FXa Is a Potent Bypassing Agent for Reversal of Direct FXa Inhibitors in Vivo". Blood 124, nr 21 (6.12.2014): 582. http://dx.doi.org/10.1182/blood.v124.21.582.582.
Pełny tekst źródłaElbaz, Carolyne, Katerina Pavenski, Hina Chaudhry, Jerome M. Teitel i Michelle Sholzberg. "The Frequency and Effect of Baseline Cross-Reacting and De Novo Inhibitors to Recombinant Porcine FVIII in Patients with Congenital and Acquired Hemophilia a". Blood 134, Supplement_1 (13.11.2019): 1128. http://dx.doi.org/10.1182/blood-2019-122260.
Pełny tekst źródłaHartmann, Rudolf, Tjerk Feenstra, Sabine Knappe, Michael Dockal i Friedrich Scheiflinger. "Elucidating the Excessive Pro-Coagulant Effect of a Sequence Identical Analogue to ACE910 in Combination with Bypassing Agents". Blood 130, Suppl_1 (7.12.2017): 90. http://dx.doi.org/10.1182/blood.v130.suppl_1.90.90.
Pełny tekst źródłaJubelirer, Steven J. "Venous Thromboembolism and Malignant Brain Tumors: A Review". Clinical and Applied Thrombosis/Hemostasis 2, nr 2 (kwiecień 1996): 130–36. http://dx.doi.org/10.1177/107602969600200208.
Pełny tekst źródłaRozprawy doktorskie na temat "Pro-hemostatic agents"
Potzeha, Fanny. "Le potentiel thérapeutique des vésicules extracellulaires hémostatiques pour le traitement ciblé des hémorragies intracérébrales : de la production à grande échelle aux tests dans des modèles pré-cliniques". Electronic Thesis or Diss., Normandie, 2021. http://www.theses.fr/2021NORMC422.
Pełny tekst źródłaIntracerebral hemorrhage (ICH) is the most severe stroke subtype. Stopping the ongoingbleeding using pro-hemostatic agents is a promising therapeutic strategy that remains limitedby serious side effects such as uncontrolled thrombosis. In the present study, we developed anoriginal therapeutic strategy for ICH based on the administration of nanosized extracellularvesicles (EVs) that can trigger the coagulation cascade specifically at the site of active bleeding.We first generated large amounts of EVs from TNF-stimulated THP-1 monocytes in bioreactors.Those monocyte-EVs presented a mean size of around 300 nm, a high pro-hemostatic activityreducing the clotting time in a dose- and TF-dependent manner and a high expression of atargeting protein on their surface (P-Selectin Glycoprotein Ligand 1, PSGL-1). In preclinicalmodels of ICH in mice, intravenous injection of mEVs improved stroke outcome in a dosedependentmanner. mEVs at 1 mg/kg prevented hematoma growth by 43% and improvedneurological score at 24h compared to control mice (p<0.01, n=15/group). These effects werealso present in more severe models of ICH (enoxaparin or warfarin treated mice). Importantly,the beneficial effect was blocked when using antibodies blocking either TF or PSGL-1,suggesting that both the pro-coagulant activity and the ability to target damaged brain vesselsare mandatory for the therapeutic efficacy of EVs. To conclude, exogenous mEVs bearing TFand PSGL-1 improve outcome after collagenase-induced ICH by acting as intravascularhemostatic patches